MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, KPTI made $146,067K in revenue. -$196,039K in net income. Net profit margin of -134.21%.

Income Overview

Revenue
$146,067K
Net Income
-$196,039K
Net Profit Margin
-134.21%
EPS
-$17.93
Unit: Thousand (K) dollars
Revenue Breakdown
    • Product
    • License And Other

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-12-31
Revenue from contract with customer, license and other revenue
146,067
Cost of sales-Product
5,949
Research and development
125,617
Selling, general and administrative
105,208
Total operating expenses
236,774
Loss from operations
-90,707
Interest income
2,773
Interest expense
45,849
(loss) gain on extinguishment of debt
-62,365
Other income (expense), net
152
Total other (expense) income, net
-105,289
Loss before income taxes
-195,996
Income tax provision
43
Net loss
-196,039
Earnings per share, basic, total
-17.93
Earnings per share, diluted, total
-17.93
Weighted average number of shares outstanding, basic, total
10,935
Weighted average number of shares outstanding, diluted
10,935
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$196,039K Income tax provision$43K Loss before incometaxes-$195,996K License And Other$31,210K Product$114,857K Total other (expense)income, net-$105,289K Loss from operations-$90,707K Other income(expense), net$152K Interest income$2,773K Revenue from contractwith customer,...$146,067K (loss) gain onextinguishment of debt-$62,365K Interest expense$45,849K Total operatingexpenses$236,774K Selling, general andadministrative$105,208K Research and development$125,617K Cost ofsales-Product$5,949K

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc. (KPTI)